Supporting the launch of a new indication for a breast cancer drug in four countries
Client:
Top-10 Global Pharmaceutical Company
Challenge:
Generate insights and data to support the launch of a new breast cancer drug in Germany, Italy, Canada, and Switzerland.
Impact:
Mapped the breast cancer disease pathways in detail across all four markets.
Quantified the future impact of introducing the drug in each health system in terms of additional capacity and resources required and their cost.
Mapped key stakeholders in each system (decision-makers, opinion leaders, etc.) whose support would be key in optimising protocols for evidence-based best practice (which included use of the new drug).
Equipped the client’s customer-facing teams, including medical affairs staff speaking to oncologists, with insights to support more intelligent and effective engagement with health system decision-makers.
